|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 106.05 EUR | -0.52% |
|
-2.08% | -4.67% |
| 03-06 | Zealand Pharma slump wipes billions off its value after obesity drug data disappoints | RE |
| 02-16 |
KBC Groep: Q4: Superior Quality Meets Upgraded Guidance | ![]() |
Evolution of the Average Target: KBC Groupe NV
Evolution of the Target Price: KBC Groupe NV
Changes in Analyst Recommendations: KBC Groupe NV
5b1028a648cd.yzf3b7IFn84mIACcDFAASAO119zl_0wI3fCrEF0xXMI.vU_DBsZn1b1rEXj7X2FWe0_np5K8pgRyhZLpYCVGKoqTWqc8g2LHrQtJNA~369dffc8218bd891ac76f2e10f27b69c
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
| +13.81% | ||||||
| +21.64% | ||||||
| +16.74% | ||||||
| +33.11% | ||||||
| +20.74% | ||||||
| +10.4% | ||||||
| +20.74% | ||||||
| +36.78% | ||||||
| +10.66% | ||||||
| -26.66% | ||||||
| Average | +15.80% | |||||
| Weighted average by Cap. | +18.02% |
Analysts' Consensus
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
106.05EUR
Average target price
121.32EUR
Spread / Average Target
+14.40%
High Price Target
145.00EUR
Spread / Highest target
+36.73%
Low Price Target
88.00EUR
Spread / Lowest Target
-17.02%
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| alphavalue | Sylvain Perret |
| Barclays | |
| KBC Securities | |
| Intesa Sanpaolo | |
| HSBC | |
| RBC Capital Markets |
Sell
Buy

Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
106.05EUR
Average target price
121.32EUR
Spread / Average Target
+14.40%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- KBC Stock
- Consensus KBC Groupe NV
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition

















